NCT03958383 - IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

January 6, 2024

Study Completion Date

August 15, 2026

Conditions

Melanoma

Interventions

BIOLOGICAL

hu14.18-IL2

A recombinant fusion protein linking the monoclonal antibody (mAb) hu14.18 with interleukin-2 (IL2), administered IT

RADIATION

Radiation Therapy

Palliative radiation therapy

BIOLOGICAL

Nivolumab

Human programmed death receptor (PD-1) blocking antibody, given IV

BIOLOGICAL

Ipilimumab

Monoclinal antibody that targets cytoxic T-lymphocyte-associated protein 4 (CTLA-4), given IV

Trial Locations (1)

University of Wisconsin Carbone Cancer Center, Madison